RxDoctor Payments Data

Kevin Gaffney, MD

Dermatology · Flint, MINPI 1194740449

Payments from drug & device makers

$1,340in general payments, 2019–2025

Across 107 payments — averaging $12.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$535
  • Novartis$366
  • Regeneron Healthcare Solutions, Inc.$178
  • Amgen$162
  • UCB, Inc.$26
  • Biogen$23
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$85764%
  • Education$48336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson39$535
Novartis43$366
Regeneron Healthcare Solutions, Inc.2$178
Amgen17$162
UCB, Inc.2$26
Biogen1$23
Dermira, Inc.1$21
LEO Pharma Inc.1$15
Biocon Biologics Inc1$14

How this compares

$1,340 in reported general payments places this provider in the 35th percentile of 404 dermatology providers in Michigan.

See all dermatology providers in Michigan

Medicare billing

Part B allowed, 2024
$881,820
Medicare patients
2,164
Services billed
12,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab112$825,933
TremfyaGuselkumab44$562,701
OtezlaApremilast119$556,345
Dupixent PenDupilumab131$477,290
StelaraUstekinumab17$385,398
Enbrel SureclickEtanercept28$316,240
Taltz AutoinjectorIxekizumab42$290,124
Skyrizi PenRisankizumab-Rzaa14$282,628
Dupixent SyringeDupilumab75$279,784
Cosentyx Unoready PenSecukinumab28$202,780
Cosentyx Sensoready (2 Pens)Secukinumab21$144,436
Taltz Autoinjector (2 Pack)Ixekizumab11$141,419
Humira(Cf)Adalimumab21$138,656
EnbrelEtanercept11$80,448
Clobetasol Propionate1,185$33,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya, Stelara$535$948,09961 claims
AmgenOtezla, Enbrel$162$636,793130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 404 dermatology providers in Michigan.

Other dermatology in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →